0.00%
-19.79%
11.27%
-25.24%
-35.83%
-63.76%
-36.68%
AI Spotlight on LBIRD
Company Description
Lumibird SA designs, manufactures, and sells various lasers for the scientific, industrial, and medical applications worldwide.It operates in two divisions, Photonics and Medical.The Photonics division offers solid-state lasers, high power laser diodes, fiber lasers, fiber amplifiers and components, photonics solutions for time-of-flight lidar and range-finding, and doppler lidar systems for wind measurement.
Its products are used in various applications, such as industrial and scientific, defense and space, and lidar sensors.The Medical division provides medical and ophthalmological solutions from diagnosis to laser treatment.The company was founded in 1970 and is headquartered in Lannion, France.
Market Data
| Last Price | 7.7 |
| Change Percentage | 0.00% |
| Open | 7.74 |
| Previous Close | 7.7 |
| Market Cap ( Millions) | 169 |
| Volume | 18755 |
| Year High | 15.48 |
| Year Low | 6.78 |
| M A 50 | 9.0 |
| M A 200 | 9.85 |
Financial Ratios
| FCF Yield | 5.04% |
| Dividend Yield | 0.00% |
| ROE | 3.37% |
| Debt / Equity | 79.53% |
| Net Debt / EBIDTA | 302.49% |
| Price To Book | 0.88 |
| Price Earnings Ratio | 26.02 |
| Price To FCF | 19.86 |
| Price To sales | 0.82 |
| EV / EBITDA | 8.72 |
News
- Jan -27 - LUMIBIRD: 2024 SALES AT €207.1M (+1.7% -REPORTED)
- Jan -24 - LUMIBIRD: FINANCIAL COMMUNICATIONS AGENDA
- Nov -27 - LUMIBIRD: EXPLORATORY PROJECT TO SELL THE MEDICAL DIVISION
- Oct -21 - LUMIBIRD: Q3 REVENUE - AGREEMENT SIGNED TO ACQUIRE THE CONTINUUM PRODUCT RANGE FROM THE AMPLITUDE LASER GROUP
- Oct -15 - LUMIBIRD: BANKS RENEW THEIR CONFIDENCE IN THE GROUP'S STRATEGY WITH FINANCING OF OVER €100M
- Sep -24 - LUMIBIRD: FIRST-HALF RESULTS FOR 2024 UP IN THE MEDICAL DIVISION, LOWER IN THE PHOTONICS DIVISION
- Aug -26 - Exploring Three High Growth Tech Stocks in France
- Jul -24 - LUMIBIRD RECEIVES NEW ORDERS FROM THALES
- Jul -22 - Lumibird: H1 2024 revenues
- May -22 - LUMIBIRD PRESENTS ITS NEW STRATEGIC PLAN
- May -03 - LUMIBIRD MEDICAL OBTAINS CE MARKING FOR C.DIAG®, A PLATFORM TO HELP DIAGNOSE DRY EYE
- Apr -05 - LUMIBIRD: PUBLICATION OF THE 2023 UNIVERSAL REGISTRATION DOCUMENT INCLUDING THE ANNUAL FINANCIAL REPORT
- Mar -25 - LUMIBIRD: ACCESS TO PREPARATORY DOCUMENTS FOR THE COMBINED GENERAL MEETING ON APRIL 29, 2024
- Mar -12 - LUMIBIRD: ANNUAL RESULTS 2023
- Feb -29 - LUMIBIRD RECEIVES LASER RANGEFINDER ORDERS FOR CV90
- Jan -29 - LUMIBIRD: 2023 REVENUES AT €203.6M
- Jan -26 - LUMIBIRD: FINANCIAL COMMUNICATIONS AGENDA
- Dec -14 - LUMIBIRD ADJUSTS ITS 2023 GROWTH TARGET
- Nov -24 - LUMIBIRD CLARIFIES ITS INTENTIONS REGARDING CILAS
- Nov -15 - LUMIBIRD : QUANTEL MEDICAL ONE OF THE FIRST WINNERS OF THE FRANCE 2030 “MEDICAL IMAGING” CALL FOR PROJECTS
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Medical
Expected Growth : 9 %
What the company do ?
Medical from Lumibird SA refers to medical laser solutions for therapeutic and diagnostic applications, offering high-precision laser systems for healthcare professionals.
Why we expect these perspectives ?
Lumibird SA's Medical segment growth is driven by increasing demand for ophthalmology and medical imaging applications, advancements in laser technology, and strategic acquisitions. The company's focus on innovation, expanding product portfolio, and strong distribution network also contribute to its 9% growth rate.
Segment n°2 -> Photonics
Expected Growth : 7 %
What the company do ?
Photonics from Lumibird SA refers to the development of high-performance laser sources and photonic components for industrial, medical, and scientific applications.
Why we expect these perspectives ?
Lumibird SA's Photonics segment growth is driven by increasing demand for high-power laser diodes in industrial and medical applications, as well as growing adoption of fiber lasers in material processing and microelectronics manufacturing. Additionally, advancements in quantum technology and LiDAR applications are expected to fuel further growth.
Lumibird Sa Products
| Product Range | What is it ? |
|---|---|
| Laser Diodes | High-power laser diodes for industrial, medical, and aerospace applications |
| Q-Switched Lasers | High-energy pulsed lasers for material processing, medical, and defense applications |
| Tunable Lasers | Wavelength-tunable lasers for spectroscopy, sensing, and metrology applications |
| Fiber Lasers | High-power fiber lasers for material processing, medical, and industrial applications |
| Ultrafast Lasers | High-intensity, ultra-short pulse lasers for material processing, spectroscopy, and microscopy |
| Laser Systems | Customized laser systems for industrial, medical, and scientific applications |
Lumibird SA's Porter Forces
Threat Of Substitutes
The threat of substitutes for Lumibird SA is moderate due to the presence of alternative technologies and products in the market.
Bargaining Power Of Customers
The bargaining power of customers is low for Lumibird SA due to the company's strong brand reputation and customer loyalty.
Bargaining Power Of Suppliers
The bargaining power of suppliers is moderate for Lumibird SA due to the presence of multiple suppliers in the market.
Threat Of New Entrants
The threat of new entrants is high for Lumibird SA due to the low barriers to entry in the market and the presence of new technologies.
Intensity Of Rivalry
The intensity of rivalry is high for Lumibird SA due to the presence of several established competitors in the market.
Strength
Capital Structure
| Value | |
|---|---|
| Debt Weight | 41.66% |
| Debt Cost | 3.95% |
| Equity Weight | 58.34% |
| Equity Cost | 10.09% |
| WACC | 7.53% |
| Leverage | 71.41% |
Lumibird SA : Quality Control
Lumibird SA passed 4 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| MYNZ | Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer … |
| CNTG | Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. It … |
| CBAV.MC | Clínica Baviera, S.A., a medical company, operates a network of ophthalmology clinics. The company is involved in the diagnosis, treatment, and monitoring of various types of visual disorders. Its clinics … |
| VIMIAN.ST | Vimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription … |
| SLV.WA | Selvita S.A. operates as a contract research organization in Poland, rest of Europe, the United States, and internationally. It operates in two segments, Contract Research Organization (CRO) services, and Bioinformatics. … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Clínica Baviera
A-Score
1-Year Total Return ->
🥈
Mainz Biomed
A-Score
1-Year Total Return ->
🥉
Selvita
A-Score
1-Year Total Return ->
4
Centogene
A-Score
1-Year Total Return ->
5
Vimian Group
A-Score
1-Year Total Return ->
6
